US ranks 1st in how its national policies impact global biopharma innovation

The USA ranks 1st in how its domestic policies support worldwide life sciences innovation, according to an analysis released last week by the Information Technology and Innovation Foundation (ITIF), a global technology policy think tank.

The findings come in a new report assessing 56 countries - which together comprise close to 90% of the world’s economy - on the extent to which their scientific research, drug pricing, and intellectual property policies contribute to global biopharmaceutical innovation.

Co-author of the report, Stephen Ezell, ITIF vice president for global innovation policy, said: “Life sciences innovation requires years of painstaking and expensive research. To ensure global health outcomes continue improving, more nations must do their share to support biopharmaceutical innovation and not free ride off the hard work and investment of the leaders.”